Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 3.51 Million USD | 334.29% |
| 2021 | 809.48 Thousand USD | 29.83% |
| 2020 | 623.48 Thousand USD | -2.63% |
| 2019 | 640.29 Thousand USD | -79.97% |
| 2018 | 3.19 Million USD | 286.44% |
| 2017 | 827.28 Thousand USD | -43.67% |
| 2016 | 1.46 Million USD | 1017.68% |
| 2015 | 131.4 Thousand USD | 938.88% |
| 2014 | 12.64 Thousand USD | -49.4% |
| 2013 | 25 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 3.46 Million USD | -1.45% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 470.08 Thousand USD | -12.69% |
| 2022 Q4 | 3.51 Million USD | 605.88% |
| 2022 Q3 | 498.03 Thousand USD | 5.94% |
| 2022 FY | 3.51 Million USD | 334.29% |
| 2022 Q1 | 538.42 Thousand USD | -33.48% |
| 2021 Q2 | 785.01 Thousand USD | -8.97% |
| 2021 FY | 809.48 Thousand USD | 29.83% |
| 2021 Q4 | 809.48 Thousand USD | 34.56% |
| 2021 Q3 | 601.55 Thousand USD | -23.37% |
| 2021 Q1 | 862.33 Thousand USD | 38.31% |
| 2020 Q1 | 1.23 Million USD | 92.93% |
| 2020 Q4 | 623.48 Thousand USD | -66.93% |
| 2020 FY | 623.48 Thousand USD | -2.63% |
| 2020 Q2 | 3.62 Million USD | 193.78% |
| 2020 Q3 | 1.88 Million USD | -48.06% |
| 2019 Q4 | 640.29 Thousand USD | -19.23% |
| 2019 Q3 | 792.71 Thousand USD | 16.19% |
| 2019 Q2 | 682.26 Thousand USD | -62.29% |
| 2019 FY | 640.29 Thousand USD | -79.97% |
| 2019 Q1 | 1.8 Million USD | -43.41% |
| 2018 Q1 | 4.18 Million USD | 406.42% |
| 2018 FY | 3.19 Million USD | 286.44% |
| 2018 Q4 | 3.19 Million USD | 305.0% |
| 2018 Q3 | 789.35 Thousand USD | -66.07% |
| 2018 Q2 | 2.32 Million USD | -44.46% |
| 2017 FY | 827.28 Thousand USD | -43.67% |
| 2017 Q4 | 827.28 Thousand USD | -66.96% |
| 2017 Q3 | 2.5 Million USD | 75.44% |
| 2017 Q2 | 1.42 Million USD | 349.18% |
| 2017 Q1 | 317.78 Thousand USD | -78.36% |
| 2016 FY | 1.46 Million USD | 1017.68% |
| 2016 Q1 | 240.93 Thousand USD | 83.35% |
| 2016 Q3 | 147.98 Thousand USD | -12.67% |
| 2016 Q2 | 169.44 Thousand USD | -29.67% |
| 2016 Q4 | 1.46 Million USD | 892.47% |
| 2015 FY | 131.4 Thousand USD | 938.88% |
| 2015 Q1 | 3365.00 USD | -73.4% |
| 2015 Q4 | 131.4 Thousand USD | 131308.0% |
| 2015 Q2 | 19.63 Thousand USD | 483.42% |
| 2015 Q3 | 100.00 USD | -99.49% |
| 2014 Q4 | 12.64 Thousand USD | -59.77% |
| 2014 Q1 | 17.22 Thousand USD | 0.0% |
| 2014 Q3 | 31.44 Thousand USD | 150.3% |
| 2014 Q2 | 12.56 Thousand USD | -27.05% |
| 2014 FY | 12.64 Thousand USD | -49.4% |
| 2013 FY | 25 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -152086.883% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -79.529% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 66.69% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -536.731% |
| Rebus Holdings, Inc. | 5000.00 USD | -70210.34% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 97.3% |
| Qrons Inc. | 420.00 USD | -836927.857% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -356.179% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 87.419% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -631.55% |
| Skye Bioscience, Inc. | 11.94 Million USD | 70.558% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 90.95% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 51.307% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -4504.234% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.72% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -145.492% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -4758.035% |
| Mesoblast Limited | 667.9 Million USD | 99.474% |
| Marizyme, Inc. | 22.01 Million USD | 84.031% |
| Genus plc | 1.02 Billion USD | 99.658% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -158.807% |
| Pharming Group N.V. | 462.85 Million USD | 99.24% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -6.112% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -604.457% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -460.689% |
| ContraFect Corporation | 20.67 Million USD | 83.0% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -800.569% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -819.866% |
| IMV Inc. | 31.33 Million USD | 88.78% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 15.207% |
| MultiCell Technologies, Inc. | 126.22 USD | -2785129.758% |
| ONE Bio Corp. | 70.08 Million USD | 94.984% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -274.115% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 97.264% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -714.316% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 90.007% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1245.513% |
| Biomind Labs Inc. | 73.81 Thousand USD | -4662.347% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.212% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -142.643% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 88.287% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -28.008% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -411.358% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -35.046% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3298.539% |
| Alpha Cognition Inc. | 2.45 Million USD | -43.364% |
| HST Global, Inc. | 1526.00 USD | -230274.64% |
| CSL Limited | 38.02 Billion USD | 99.991% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -255.833% |
| Halberd Corporation | 10.13 Thousand USD | -34600.592% |
| Enzolytics Inc. | 361.7 Million USD | 99.028% |
| Agentix Corp. | 261.39 Thousand USD | -1244.921% |
| Resverlogix Corp. | 8.11 Million USD | 56.679% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -87.207% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.923% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 92.63% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -449.595% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -15331.794% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 60.717% |
| AVAX Technologies, Inc. | 7.37 Million USD | 52.346% |
| Zenith Capital Corp. | 7410.00 USD | -47342.874% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.896% |
| Ember Therapeutics, Inc. | 184.00 USD | -1910507.065% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -992.434% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1245.066% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -278.843% |
| Kadimastem Ltd | 2.3 Million USD | -52.578% |
| Helix BioMedix, Inc. | 3.02 Million USD | -16.212% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 93.329% |
| BioStem Technologies, Inc. | 14.56 Million USD | 75.855% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -6057.419% |
| LadRx Corporation | 2.3 Million USD | -52.327% |
| Cell Source, Inc. | 195.17 Thousand USD | -1701.25% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -894.16% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -894.16% |
| NovAccess Global Inc. | 62.24 Thousand USD | -5547.598% |
| Affymax, Inc. | 7.44 Million USD | 52.767% |
| Itoco Inc. | 1.4 Million USD | -151.095% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -3575.128% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3216.525% |
| Mobile Lads Corp. | 52.00 USD | -6760509.615% |
| CytoDyn Inc. | 11.13 Million USD | 68.431% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2358.885% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -19561.728% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -812.006% |
| SYBLEU INC | 330.46 Thousand USD | -963.8% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -758.654% |
| International Stem Cell Corporation | 5.39 Million USD | 34.777% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2454.176% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 76.566% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 78.795% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -4350.022% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -306.57% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 53.232% |
| Neutra Corp. | 2851.00 USD | -123208.208% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 89.152% |
| PureTech Health plc | 693.97 Million USD | 99.493% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 56.443% |
| IXICO plc | 15.84 Million USD | 77.812% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 57.552% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.598% |
| CSL Limited | 38.02 Billion USD | 99.991% |
| Cellectis S.A. | 333.99 Million USD | 98.947% |